Letters to the editor

Clinical Therapeutics

Volumn 24, Issue 5, 2002, Pages 835-836

  Roll, Kevin T ^a  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; RISEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DRUG DERIVATIVE; ETIDRONIC ACID;

DRUG EFFICACY; DRUG INDICATION; HIP FRACTURE; HUMAN; LETTER; POSTMENOPAUSE OSTEOPOROSIS; RISK MANAGEMENT; VERTEBRA FRACTURE; AGED; FEMALE; FRACTURE; NOTE; OSTEOPOROSIS; POSTMENOPAUSE;

AGED; DIPHOSPHONATES; ETIDRONIC ACID; FEMALE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; POSTMENOPAUSE;

EID: 0036583892     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(02)85156-6     Document Type: Letter

References (6)

1. Risedronate: A new oral bisphosphonate
2. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial
3. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy
4. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
5. Risk of new vertebral fracture in the year following a fracture
6. Effect of risedronate on the risk of hip fracture in elderly women